Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.
Aktas O, Ziemssen F, Ziemssen T, Klistorner A, Butzkueven H, Izquierdo G, Leocani L, Balcer LJ, Galetta SL, Castrillo-Viguera C, Bradley DP, Naylor ML, Belachew S, Franchimont N, Zhu B, Cheng W; RENEWED Investigators. Aktas O, et al. Among authors: naylor ml. Mult Scler Relat Disord. 2024 Nov 24;93:106185. doi: 10.1016/j.msard.2024.106185. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39662163 Free article.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X. Cohen JA, et al. Among authors: naylor ml. Mult Scler. 2022 Jun;28(7):1131-1137. doi: 10.1177/13524585211061343. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994577 Free PMC article.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
Salvetti M, Wray S, Nelles G, Altincatal A, Kumar A, Koster T, Naylor ML; Plegridy Observational Program investigators. Salvetti M, et al. Among authors: naylor ml. Mult Scler Relat Disord. 2022 Jan;57:103350. doi: 10.1016/j.msard.2021.103350. Epub 2021 Oct 29. Mult Scler Relat Disord. 2022. PMID: 35158459 Free article.
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD, Scott TF, Arnold DL, Altincatal A, Naylor ML. Newsome SD, et al. Among authors: naylor ml. Mult Scler Relat Disord. 2022 Jan;57:103367. doi: 10.1016/j.msard.2021.103367. Epub 2021 Nov 3. Mult Scler Relat Disord. 2022. PMID: 35158473 Free article. Clinical Trial.
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Cutter G, Rudick RA, de Moor C, Singh CM, Fisher E, Koster T, Lublin FD, Wolinsky JS, McFarland H, Jacobson S, Naylor ML. Cutter G, et al. Among authors: naylor ml. Mult Scler J Exp Transl Clin. 2023 Apr 27;9(2):20552173231169463. doi: 10.1177/20552173231169463. eCollection 2023 Apr-Jun. Mult Scler J Exp Transl Clin. 2023. PMID: 37139460 Free PMC article.
20 results